bullish
high
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
60%Questions answered1Evaded / deflected10Questions auditedContradictedNumbers vs filing
Partial answer
Medium priority
Generic pricing trends in US and thoughts on Chinese pharma market 2024.
Asked by Michaela (on behalf of Balaji Prasad), Barclays
Described environment qualitatively but gave no numbers or specific outlook.
no specific pricing trend quantificationno forward guidance
Read the exchange
Question
First one is, what is your latest thinking on generic pricing trends, particularly in the U.S.? And could you provide a bit more color on how you see this trending going forward? And second one, what are your thoughts around the Chinese pharma market in 2024?
Erez Israeli, CEO
So the first question, we give the continuation of the pricing environment that we saw in the last couple of quarters... As for China, we do see a very good tracking of our approvals. We got nine approvals since the beginning of this fiscal, and three in the last quarter.
Partial answer
Medium priority
Reason for fewer US filings and pending ANDAs decline.
Asked by Kunal Dhamesha, Macquarie
Confirmed focus but gave no concrete numbers or timeline for filings.
no specific number of future filingsvague timing
Read the exchange
Question
So if I look at the first nine-month data, we have launched 12 products in the US, and we have just done 8 new filings, and our total pending ANDAs also have come down from 90 in quarter four FY 2022, to now 79. So is it because we are focusing on few therapy areas, more complex?
Erez Israeli, CEO
So yes, we do have less filings, let's say overall, because we are really focused on products that we believe is critical, but it's still in healthy numbers of files. I believe that you'll see in the next coming months more filings which are coming, just timing of those files.
Evasive
Medium priority
Details on MenoLabs acquisition: sales, value, and borrowing link.
Asked by Kunal Dhamesha, Macquarie
Did not provide requested sales, value, or borrowing details.
no specific sales figureno acquisition valueno borrowing link
Read the exchange
Question
And then, just a follow-up on that, you know, we are, now we have acquired this MenoLabs. If you can provide some, a minute clarity as to how does this fit into our strategy, what was probably the last 12 months sales for these brands, and, what is the acquisition value that we have paid? And, does the increase in borrowing, quarter-on-quarter relate to this?
Erez Israeli, CEO
So, as far as the timeline of what we call Horizon Two... I don't recall exactly the sales of MenoLabs before, but we are talking about the range of $ millions here. So this is a very ... So it's relatively small.
Answered
Medium priority
US OTC/wellness revenue contribution after MenoLabs.
Asked by Kunal Dhamesha, Macquarie
Provided a specific percentage for OTC contribution.
Read the exchange
Question
After this, what would be our U.S. revenue contribution from the wellness product or OTC product? I think earlier we used to provide it in 20 years or the quarterly filing. I'm not sure now we provide that.
Erez Israeli, CEO
The OTC, if I may, on an annual basis, should be about 10% give or take, of the overall U.S. business.
Answered
Low priority
Reason for quarter-on-quarter receivables increase and which markets.
Asked by Tushar Manudhane, Motilal Oswal Financial Services
Clearly attributed to top line growth and identified US concentration.
Read the exchange
Question
So firstly, on the receivables, which have increased on a quarter-on-quarter basis, is this on certain select products or is it across the portfolio? And for which markets?
Erez Israeli, CEO
No, receivables increase is primarily in line with the top line increase, so it's nothing unusual. It's across the markets, but largely concentrated in the U.S.
Partial answer
Low priority
Reason for higher PSAI segment gross margin this quarter.
Asked by Tushar Manudhane, Motilal Oswal Financial Services
Explained generally but did not quantify mix or other factors.
no specific product mix details
Read the exchange
Question
Secondly, gross margin for PSAI segment has been higher for the quarter compared to the previous quarters. So anything in specific you'd like to comment?
Erez Israeli, CEO
Yeah, we are growing, and because of the nature of the business, that it has normally a high level of fixed costs. So when you are increasing the sales, you normally will have better margins.
Partial answer
High priority
When will higher SG&A spend start contributing to revenue and operating leverage?
Asked by Neha Manpuria, Bank of America
Gave qualitative timeline but no quantified impact on revenue or margins.
no specific revenue contribution numbersvague timeline
Read the exchange
Question
If I were to look at the SG&A spend increase that we have seen in the quarter... from a monetization point of view, when should we start seeing this contributing to revenue? And do you think this number continues to trend up from where we are?
Erez Israeli, CEO
So part of it... will give results already in FY 2025... Some of it... will take more time... likely that this level... will continue to be a bit higher, but I do see more growth in revenue.
Partial answer
High priority
How many of the 2025 US launches are meaningful to offset base business?
Asked by Neha Manpuria, Bank of America
Provided number of potential products but no breakdown or sales estimates.
no specific count of meaningful launchesuncertainty on sales
Read the exchange
Question
Out of the 2025 launches that you talk about in the U.S., can we try to understand as to, you know, how many of these could be the bread and butter launches that we need to offset the base business? And how many of these could be meaningful products?
Erez Israeli, CEO
So we have, overall, about 26 products that can be launched to get the full value... meaningful, probably, $10 million and more than that... The question is what combination of that will actually get to the market, and what will be the sales? That, of course, I don't know.
Answered
High priority
Timeline for the 26 meaningful US products.
Asked by Neha Manpuria, Bank of America
Provided clear timeline of 2025-2026 for the 26 products.
Read the exchange
Question
The 26 products would be, you know, over the next 2 years, 3 years? How should I look at the timeline for that?
Erez Israeli, CEO
So potentially... I refer to products that are supposed to be in the next two years, 2025 and 2026, if it's going to 2027, we have more products.
Answered
High priority
Biosimilar pipeline: number of products and timeline for US/EU.
Asked by Neha Manpuria, Bank of America
Provided specific number of products and timeline for launches.
Read the exchange
Question
On the biosimilar pipeline... could we talk about how many products you are developing for the U.S. and European market? And when should we start expecting some sort of a timeline or progress update?
Erez Israeli, CEO
So we are talking about six products by FY 2030... The first product should come in the beginning of calendar 2027, and then the rest of the products by FY 2030.
Partial answer
Medium priority
How will India business bridge growth until innovative products deliver?
Asked by Damayanti Kerai, HSBC Securities and Capital Markets India
Explained adjustments but did not quantify bridge growth rate.
no specific growth rate for bridge periodrelies on adjusted base
Read the exchange
Question
I just want to understand, like, how far these opportunities are right now for you, because it appears that these kind of product uptake might take some time, and meanwhile, your India business is growing slowly within the market. So how do you bridge your growth versus market growth till the time those innovative products start delivering results?
Erez Israeli, CEO
First, just to calibrate, part of the reason that people see single digits is that business... contribute about 3% of that decline... if we are taking those, we are already in the place of double digits... In April 2025, I'm expecting to see double-digit growth in new business from the big brands.
Partial answer
High priority
Risk assessment of Bachupally facility inspection and potential OAI.
Asked by Surya Patra, PhillipCapital
Acknowledged risk but gave no assessment of likelihood or business impact.
no probability estimateno impact quantification
Read the exchange
Question
Regarding the inspection outcomes for the Bachupally facility, so what risk that one should assign to it, or what is your practical assessment here? So do you find any risk to the existing business, given the kind of number of observations that has been issued to you, and the nature of the observation that has been highlighted?
Erez Israeli, CEO
So, first of all, what is the risk? The risk is that you get an OAI. Is there a possibility for that? Yes, there is a possibility... I believe that it's a robust answer, but of course, we will wait for the FDA response for that.
Quantitative claims vs filed numbers
| Claim | Management said | Filing | Verdict |
|---|---|---|---|
| PSAI Q3 revenue INR 1040 cr, gross margin ~22% | ₹1,040 cr | ₹7,215 cr | Understated vs filing |
| PSAI Q2 revenue INR 960 cr, gross margin 13% | ₹960 cr | ₹7,215 cr | Understated vs filing |
Filed figures sourced from Screener.in. Claims within a small tolerance of the filing are marked “matches filing”.